Protalix BioTherapeutics, Inc. Stock TEL AVIV STOCK EXCHANGE
Stocks
PLX
US74365A3095
Pharmaceuticals
|
Delayed
TEL AVIV STOCK EXCHANGE
11:24:48 2023-03-21 am EDT
|
5-day change | 1st Jan Change | ||
| 732.50 ILa | -.--% |
|
+3.29% | +69.68% |
| Market Cap | 189M 0 162M 152M 139M 262M 18.1B 266M 1.79B 701M 9.08B 711M 695M 30.01B | P/E 2026 * |
12.4x | P/E 2027 * | 42.7x |
|---|---|---|---|---|---|
| Enterprise Value | 189M 0 162M 152M 139M 262M 18.1B 266M 1.79B 701M 9.08B 711M 695M 30.01B | EV / Sales 2026 * |
2.37x | EV / Sales 2027 * | 2.78x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix BioTherapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 59 | 2019-06-29 |
Gilad Mamlok
DFI | Director of Finance/CFO | 57 | 2025-08-23 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 2024-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 2008-06-30 |
Aharon Schwartz
BRD | Director/Board Member | 83 | 2014-10-31 |
Dror Bashan
BRD | Director/Board Member | 59 | 2019-06-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +3.29% | - | - | 189M | |
| +4.46% | +4.92% | +82.07% | +134.31% | 1,141B | |
| +0.85% | +4.81% | +53.77% | +58.51% | 659B | |
| +2.72% | +6.92% | +28.99% | +77.15% | 470B | |
| +0.31% | +0.52% | +41.20% | +44.05% | 366B | |
| +0.45% | +2.35% | +25.99% | +42.21% | 302B | |
| +0.60% | +2.97% | +2.27% | +13.06% | 254B | |
| +4.02% | +6.29% | +49.67% | +68.96% | 239B | |
| -0.43% | -0.02% | -13.96% | -52.13% | 207B | |
| +2.90% | +8.63% | +25.11% | +94.52% | 183B | |
| Average | +1.24% | +4.10% | +32.79% | +53.40% | 424.55B | |
| Weighted average by Cap. | +1.17% | +4.31% | +47.06% | +74.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 79.8M 0 68.45M 63.92M 58.64M 110M 7.63B 112M 754M 295M 3.83B 300M 293M 12.65B | 68.19M 0 58.5M 54.62M 50.12M 94.24M 6.52B 95.79M 645M 252M 3.27B 256M 250M 10.81B |
| Net income | 15.38M 0 13.19M 12.32M 11.3M 21.25M 1.47B 21.6M 145M 56.9M 737M 57.73M 56.47M 2.44B | 4.46M 0 3.83M 3.57M 3.28M 6.17M 427M 6.27M 42.18M 16.52M 214M 16.76M 16.39M 707M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PLX Stock
- PLX Stock
Select your edition
All financial news and data tailored to specific country editions
